Drug-gut Microbiome Interaction in Atherosclerosis Therapeutics.

Atherosclerosis (AS) is one of the major risk factors for cardiovascular disease pathogenesis, and current studies have found that the development of atherosclerosis is closely related to the intestinal microbiome. This review describes the relationship between the development of atherosclerosis and the gut microbiome with its metabolites and reviews the interactions between atherosclerosis-related drugs and the intestinal microbiome, especially the in vivo metabolic effects of the intestinal microbiome on drugs related to the treatment of atherosclerosis, to provide further understanding for the development of drugs based on the intestinal microbiome to treat atherosclerosis.